Clinical Research Directory
Browse clinical research sites, groups, and studies.
Canagliflozin Targeting Vascular Inflammation
Sponsor: Ottawa Heart Institute Research Corporation
Summary
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.
Official title: Canagliflozin Targeting Vascular Inflammation: an Ottawa Imaging Study - a Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2024-11-15
Completion Date
2026-12
Last Updated
2024-12-11
Healthy Volunteers
No
Conditions
Interventions
Canagliflozin
Canagliflozin tablet 300mg PO daily
Placebo
Placebo tablet
Locations (1)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada